Why aHUS for them and not me
Earlier this year in the series of articles following the Rare Disease Day video one featured a question by Elisabeth from…
Trial watch 16 -Factor D complement inhibitor.
One of the ways to find out which drugs have a potential for aHUS treatment is to look at trials for…
Autoantibodies cause aHUS
Another question from the RDD2022 video. This one from Harry in Hartlepool UK. This one is about anti factor h autoantibodies.…
Will there be a cure for aHUS one day?
Answers to the RDD2022 video continue. Samantha asks will there ever be a cure for aHUS? Crikey that is a difficult…
aHUS Trial Watch 14
A trial has been designed by Alexion to examine the efficacy of Ravulizumab to treat those with a Thrombotic Microngiopathy ,…
aHUS and COVID 19 Vaccine Update Update
Article No. 424 19 March 2021 COVID 19 vaccine supplies are being hampered around the world because of uncertainty about a…
BB5.1 aHUS connection to c.3643C>G; p. Arg1215Gly
Article No 413 23 January 2021 Very few people have heard of BB5.1 nor even c.3643C>G; p. Arg1215Gly. Yet both are of…
Help needed to join the aHUS dots
Article No 395 25 November 2020 This was a call to action to the Global aHUS community.( Results to come) It…
OMS721: Omeros Research Collaboration with University of Cambridge
Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?